Read by QxMD icon Read


Hans-Christian Kolberg, Gyoergy Loevey, Leyla Akpolat-Basci, Miltiades Stephanou, Peter A Fasching, Michael Untch, Max Bulsara, Jayant S Vaidya, Cornelia Liedtke
INTRODUCTION: Targeted intraoperative radiotherapy (TARGIT - IORT) as a tumour bed boost after breast conserving surgery is well established for women with early breast cancer. A previous study from our group shows a beneficial effect of TARGIT-IORT on overall survival (OS) but not disease-free survival (DFS) after neoadjuvant chemotherapy compared to an external boost suggesting a potential non-inferiority of TARGIT-IORT. In this study we present results regarding the high-risk subset of patients (i...
February 1, 2017: Reviews on Recent Clinical Trials
Felix Sedlmayer, Roland Reitsamer, Frederik Wenz, Elena Sperk, Christoph Fussl, Julia Kaiser, Ingrid Ziegler, Franz Zehentmayr, Heinz Deutschmann, Peter Kopp, Gerd Fastner
The term IORT (intraoperative radiotherapy) is currently used for various techniques that show huge differences in dose delivery and coverage of the tissue at risk. The largest evidence for boost IORT preceding whole breast irradiation (WBI) originates from intraoperative electron treatments (IOERT) with single doses around 10 Gy. At median follow-up periods at 6 years, outstandingly low local recurrence rates of less than 1% are observed. Higher local relapse rates were described for G3 tumors and triple negative breast cancers as well as for IORT following primary systemic treatment for locally advanced tumors...
January 19, 2017: Radiation Oncology
Hans-Christian Kolberg, Gyoergy Loevey, Leyla Akpolat-Basci, Miltiades Stephanou, Peter A Fasching, Michael Untch, Cornelia Liedtke, Max Bulsara, Jayant S Vaidya
INTRODUCTION: The use of targeted intraoperative radiotherapy (TARGIT-IORT) as a tumour bed boost during breast-conserving surgery (BCS) for breast cancer has been reported since 1998. We present its use in patients undergoing breast conservation following neoadjuvant therapy (NACT). METHOD: In this retrospective study involving 116 patients after NACT we compared outcomes of 61 patients who received a tumour bed boost with IORT during lumpectomy versus 55 patients treated in the previous 13 months with external (EBRT) boost...
January 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Eric Lambaudie, Gilles Houvenaeghel, Amira Ziouèche, Sophie Knight, François Dravet, Jean Remy Garbay, Sylvie Giard, Hélène Charitansky, Monique Cohen, Christelle Faure, Delphine Hudry, Paul Azuar, Richard Villet, Pierre Gimbergues, Christine Tunon de Lara, Agnès Tallet, Marie Bannier, Mathieu Minsat, Michel Resbeut
BACKGROUND: To estimate the proportion of elderly patients (>70 years) with breast cancer eligible for an Exclusive IntraOperative RadioTherapy (E-IORT) and to evaluate their local recurrence-free survival rate. METHODS: This retrospective study examining two cohorts focuses on patients over 70 years old: a multi-centric cohort of 1411 elderly patients and a mono-centric cohort of 592 elderly patients. All patients underwent conservative surgery followed by external radiotherapy for T0-T3 N0-N1 invasive breast cancer, between 1980 and 2008...
November 15, 2016: BMC Surgery
Jayant S Vaidya, Frederik Wenz, Max Bulsara, Jeffrey S Tobias, David J Joseph, Christobel Saunders, Chris Brew-Graves, Ingrid Potyka, Stephen Morris, Hrisheekesh J Vaidya, Norman R Williams, Michael Baum
BACKGROUND: Based on our laboratory work and clinical trials we hypothesised that radiotherapy after lumpectomy for breast cancer could be restricted to the tumour bed. In collaboration with the industry we developed a new radiotherapy device and a new surgical operation for delivering single-dose radiation to the tumour bed - the tissues at highest risk of local recurrence. We named it TARGeted Intraoperative radioTherapy (TARGIT). From 1998 we confirmed its feasibility and safety in pilot studies...
September 2016: Health Technology Assessment: HTA
F Wenz
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Y Abo-Madyan, G Welzel, E Sperk, C Neumaier, A Keller, S Clausen, F Schneider, M Ehmann, F Wenz
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Tammy Corica, Anna K Nowak, Christobel M Saunders, Max Bulsara, Mandy Taylor, Jayant S Vaidya, Michael Baum, David J Joseph
PURPOSE: To report the first comprehensive investigation of patient-reported cosmesis and breast-related quality of life (QOL) outcomes comparing patients randomized to risk-adapted single-dose intraoperative radiation therapy (TARGIT-IORT) versus external beam radiation therapy (EBRT) on the TARGIT-A trial. METHODS AND MATERIALS: Longitudinal cosmesis and QOL data were collected from a subset of TARGIT-A participants who received TARGIT-IORT as a separate procedure (postpathology)...
September 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Melinda Epstein, Melvin Silverstein, Kevin Lin, Brian Kim, Sadia Khan, Cristina De Leon, Lisa Guerra, Lincoln Snyder, Colleen Coleman, January Lopez, Ralph Mackintosh, Peter Chen
INTRODUCTION: Intraoperative radiation therapy (IORT) permits the delivery of radiation therapy directly to the tumor bed at the time of surgery. Minimal data are available about the complications associated with this modality of treatment using the Xoft(®) Axxent Electronic Brachytherapy (Axxent) System. METHODS: A total of 702 patients who received IORT using the Xoft(®) Axxent System at Hoag Memorial Hospital Presbyterian between June 2010-February 2016 were accrued in an IORT data registry study...
October 2016: Annals of Surgical Oncology
Emanuela Esposito, Rita Compagna, Massimo Rinaldo, Sara Falivene, Vincenzo Ravo, Bruno Amato, Paolo Muto, Massimiliano D'Aiuto
INTRODUCTION: Screening and adjuvant postoperative therapies have increased survival amongst women with breast cancer, but these tools are seldom applied in elderly patients. Higher rates of local recurrence occur in those elderly patients who avoid radiotherapy. TARGIT-A and ELIOT trials has been reported to not to be inferior to external beam RT in suitable subgroups of patients. The TARGIT-Elderly trial has been launched in order to confirm the efficacy of intraoperative radiotherapy (IORT) in a well selected group of elderly patients who are more likely to decline radiation treatment...
September 2016: International Journal of Surgery
Michela Massa, Simonetta Franchelli, Renzo Panizza, Tiberio Massa
After the results obtained in the two randomized clinical trial, the ELIOT trial and the TARGIT-A trial, a heated debate is going on concerning the question of applying intraoperative radiotherapy (IORT) instead of postoperative whole breast irradiation (WBI) after breast conservative treatment. Currently, many centers are applying the IORT following the strict selection criteria dictated by the working groups American Society for Radiation Oncology (ASTRO) and Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) and monitoring the oncological outcome together with radiation toxicity on breast tissue...
April 2016: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
Nathan J Coombs, Joel M Coombs, Uma J Vaidya, Julian Singer, Max Bulsara, Jeffrey S Tobias, Frederik Wenz, David J Joseph, Douglas A Brown, Richard Rainsbury, Tim Davidson, Douglas J A Adamson, Samuele Massarut, David Morgan, Ingrid Potyka, Tammy Corica, Mary Falzon, Norman Williams, Michael Baum, Jayant S Vaidya
OBJECTIVE: To quantify the journeys and CO2 emissions if women with breast cancer are treated with risk-adapted single-dose targeted intraoperative radiotherapy (TARGIT) rather than several weeks' course of external beam whole breast radiotherapy (EBRT) treatment. SETTING: (1) TARGIT-A randomised clinical trial (ISRCTN34086741) which compared TARGIT with traditional EBRT and found similar breast cancer control, particularly when TARGIT was given simultaneously with lumpectomy, (2) 2 additional UK centres offering TARGIT...
May 9, 2016: BMJ Open
Stephanie A Valente, Rahul D Tendulkar, Sheen Cherian, Colin O'Rourke, Jon M Greif, Lisa Bailey, Valery Uhl, Kevin P Bethke, Eric D Donnelly, Ray Rudolph, Aaron Pederson, Thomas Summer, S Chace Lottich, Darrel L Ross, Christine Laronga, Loretta Loftus, Andrea M Abbott, Pond Kelemen, Ulrich Hermanto, Neil B Friedman, Gauri C Bedi, Jennifer E Joh, William A Thompson, Richard A Hoefer, Jason P Wilson, Song K Kang, Barry Rosen, James Ruffer, Luis Bravo, Alice Police, Jamie M Escallon, Anthony W Fyles, David R McCready, Gregory M Graves, Nitin Rohatgi, Joyce A Eaker, Jannine Graves, Shawna C Willey, Eleni A Tousimis, Brian T Collins, Christina M Shaw, Lee Riley, Nimisha Deb, Tricia Kelly, David L Andolino, Marc E Boisvert, Joanne Lyons, William Small, Stephen R Grobmyer
BACKGROUND: Single-dose intraoperative radiotherapy (IORT) is an emerging treatment for women with early stage breast cancer. The objective of this study was to define the frequency of IORT use, patient selection, and outcomes of patients treated in North America. METHODS: A multi-institutional retrospective registry was created, and 19 institutions using low-kilovoltage IORT for the treatment of breast cancer entered data on patients treated at their institution before July 31, 2013...
September 2016: Annals of Surgical Oncology
Mace Coday, Phyllis Richey, Fridtjof Thomas, Quynh T Tran, Sarah B Terrell, Fran Tylavsky, Danielle Miro, Margaret Caufield, Karen C Johnson
Multiple recruitment strategies are often needed to recruit an adequate number of participants, especially hard to reach groups. Technology-based recruitment methods hold promise as a more robust form of reaching and enrolling historically hard to reach young adults. The TARGIT study is a randomized two-arm clinical trial in young adults using interactive technology testing an efficacious proactive telephone Quitline versus the Quitline plus a behavioral weight management intervention focusing on smoking cessation and weight change...
April 15, 2016: Contemporary Clinical Trials Communications
Jo Picot, Vicky Copley, Jill L Colquitt, Neelam Kalita, Debbie Hartwell, Jackie Bryant
BACKGROUND: Initial treatment for early breast cancer is usually either breast-conserving surgery (BCS) or mastectomy. After BCS, whole-breast external beam radiotherapy (WB-EBRT) is the standard of care. A potential alternative to post-operative WB-EBRT is intraoperative radiation therapy delivered by the INTRABEAM(®) Photon Radiotherapy System (Carl Zeiss, Oberkochen, Germany) to the tissue adjacent to the resection cavity at the time of surgery. OBJECTIVE: To assess the clinical effectiveness and cost-effectiveness of INTRABEAM for the adjuvant treatment of early breast cancer during surgical removal of the tumour...
August 2015: Health Technology Assessment: HTA
Anthony Zietman
No abstract text is available yet for this article.
August 1, 2015: International Journal of Radiation Oncology, Biology, Physics
Jayant S Vaidya, Max Bulsara, Frederik Wenz, David Joseph, Christobel Saunders, Samuele Massarut, Henrik Flyger, Wolfgang Eiermann, Michael Alvarado, Laura Esserman, Mary Falzon, Chris Brew-Graves, Ingrid Potyka, Jeffrey S Tobias, Michael Baum
No abstract text is available yet for this article.
July 1, 2015: International Journal of Radiation Oncology, Biology, Physics
Emanuela Esposito, Bauke Anninga, Ian Honey, Gillian Ross, Dick Rainsbury, Siobhan Laws, Sygriet Rinsma, Michael Douek
Two large randomised controlled trials of intraoperative radiotherapy (IORT) in breast-conserving surgery (TARGIT-A and ELIOT) have been published 14 years after their launch. Neither the TARGIT-A trial nor the ELIOT trial results have changed the current clinical practice for the use of IORT. The in-breast local recurrence rate (LRR) after IORT met the pre-specified non-inferiority margins in both trials and was 3.3% in TARGIT-A and 4.4% in the ELIOT trial. In both trials, the pre-specified estimates for local recurrence (LR) with external beam radiation therapy (EBRT) significantly overestimated actual LRR...
2015: Ecancermedicalscience
E Esposito, B Anninga, S Harris, I Capasso, M D'Aiuto, M Rinaldo, M Douek
BACKGROUND: Intraoperative radiotherapy (IORT) constitutes a paradigm shift from the conventional 3-5 weeks of whole-breast external beam radiotherapy (EBRT). IORT enables delivery of radiation at the time of excision of the breast tumour, targeting the area at highest risk of recurrence, while minimizing excessive radiation exposure to healthy breast tissue. The rationale for IORT is based on the observation that over 90 per cent of local recurrences after breast-conserving surgery occur at or near the original operation site...
May 2015: British Journal of Surgery
Dennis R Holmes
The findings of the TARGIT A and ELIOT prospective, randomized controlled trials provide compelling data regarding the efficacy and safety of single fraction intraoperative radiotherapy as an alternative to standard postoperative radiotherapy in the management of early-stage breast cancer. This editorial summarizes the findings of both studies and discusses the importance of patient selection in identifying potential candidates for intraoperative radiotherapy.
March 2015: Breast Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"